<DOC>
	<DOCNO>NCT01045863</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability single administration PF-03382792 healthy volunteer . ; evaluate plasma drug level biological activity .</brief_summary>
	<brief_title>To Evaluate Safety , Tolerability , Plasma Drug Levels And Other Biological Effects In Healthy Volunteers</brief_title>
	<detailed_description>Evaluate safety , tolerability , plasma concentration PF-03382792 biological activity follow single dose PF-03382792 . Three ascend single dos PF-03382792 administer study ( 0.05 mg , 0.15mg 0.5 mg ) . The decision terminate study make June 4 , 2010 due safety finding limitation regard level metabolite project dose 0.5 mg .</detailed_description>
	<criteria>For cohort , healthy male and/or female subject nonchildbearing potential age 18 55 year , inclusive . Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic disease . History regular alcohol consumption exceed 7 drinks/week female 14 drinks/week male ( 1 drink = 5 ounce ( 150 mL ) wine 12 ounce ( 360 mL ) beer 1.5 ounce ( 45 mL ) hard liquor ) within 6 month Screening . Signs symptoms adrenal insufficiency . Ocular lens ( eye ) abnormality .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>volunteer</keyword>
</DOC>